
Table of Contents

Preface.....	xiii
About the Editors	xv
1. Introduction to Cellular Therapy Products and Apheresis.....	1
<i>Zbigniew M. Szczepiorkowski, MD, PhD, FCAP, FRSM, and Jeffrey L. Winters, MD</i>	
Status of Apheresis in Cell and Gene Therapy	2
The Future of Apheresis in Cellular and Gene Therapy	3
Conclusions.....	6
Suggested Readings	6
2. Equipment.....	9
<i>Edwin A. Burgstaler, MT, HP(ASCP), and Michael C. Deeds</i>	
Principles of Operation	9
Apheresis Cell Collection Equipment	11
Photopheresis Equipment	24
Cell Processing Equipment	27
Summary	33
Suggested Readings	33
3. Cellular Therapy Donor Evaluation	45
<i>Meghann R. Cody, DNP, APRN, NP-C, and John P. Miller, MD, PhD</i>	
Types of Hematopoietic Progenitor Cell Donation.....	46
Donor Consent for HPC Donation.....	47
Medical Evaluation of HPC Donors	50
Subsequent Donations.....	61
Mononuclear Cell Donation for Cellular Therapy and Biotherapies	62
Suggested Readings	62
4. Vascular Access	65
<i>Jaleah Hawkins, MD; Brianna Cunigan, MSN, RN, QIA; Sorelle Jefcik, BSN, RN, QIA; and Jenna Khan, MD</i>	
General Principles	66
Peripheral Access.....	66

Apheresis Principles and Practice

Central Venous Catheters	70
Ports	74
AV Fistulas and Grafts	82
Pediatrics	83
Alternative Access: Midline Catheters	85
Suggested Readings	85
 5. Characteristics of Cellular Therapy Products Collected by Apheresis	87
<i>Kyle Annen, DO; Bryce Pasko, MD; Joseph Schwartz, MD, MPH; Zbigniew M. Szczepiorkowski, MD, PhD, FCAP, FRSM; and Suzanne R. Thibodeaux, MD, PhD</i>	
Mobilization Considerations	88
Collection Mathematics	88
Adverse Events	88
Labeling	92
Fact Sheets to Aid in Product Characterization	92
Conclusions	123
Suggested Readings	124
 6. Processing of Cellular Therapy Products	127
<i>Opal L. Reddy, MD; Sandhya R. Panch, MD, MPH; David H. McKenna, MD; David F. Stroncek, MD; and Shelly M. Williams, MD</i>	
General Principles	128
Processing Steps for Cellular Therapies	130
Equipment and Processing	140
QC Testing	146
Conclusions	149
Suggested Readings	149
 7. The Cryopreservation of Apheresis Products in Cell Therapy	151
<i>Nishaka William, MSc; Anusha Sajja, MBBS; and Jason P. Acker, MBA, PhD</i>	
The Fundamentals of Cryopreservation	153
A Brief Overview of Red Cell, Platelet, and Granulocyte Cryopreservation	157
The Cryopreservation of Peripheral Blood Monocytes and Lymphocytes for Adoptive Cell Therapies: How the Current Standard of Cryopreservation Influences the Final Product and the Manufacturing Process	160
The Cryopreservation of Hematopoietic Progenitor Cells	165
Novel Opportunities to Improve the Cryopreservation of Apheresis Blood Products	168
Conclusions	171
Suggested Readings	171

Table of Contents

8. Proficiency Testing	173
<i>Matthew Karafin, MD, MS; Zbigniew M. Szczepiorkowski, MD, PhD, FCAP, FRSM; and Yara Park, MD</i>	
Proficiency Test Requirements	174
Commercial Options for Cell Therapy Proficiency Testing	176
Summary and Future Outlook	179
Suggested Readings	179
9. Caring for Patients Receiving Cellular Therapy Products	181
<i>Michael Linenberger, MD, FACP, and Sherilyn Tuazon, MD, MS</i>	
CT Product Manipulations, Components, and Patient Factors Relevant to	
Infusion-Related Adverse Events	183
Standards and Guidance from Regulatory Agencies and Accreditation Bodies	190
Infusion of Minimally Manipulated Fresh HPC and MNC CT Products	191
Infusion of Minimally Manipulated Cryopreserved CT Products	196
Care of Patients Receiving Immune Effector Cell Therapy	201
Suggested Readings	210
10. Extracorporeal Photopheresis	215
<i>Kristen N. Ruby, DO, MPH; Maxwell T. Roth, MD; Zbigniew M. Szczepiorkowski, MD, PhD, FCAP, FRSM; and Jennifer Schneiderman, MD, MS</i>	
Mechanics of the ECP Procedure	216
Proposed Mechanisms of Action of ECP	220
Patient Preparation and Counseling about ECP	221
Contraindications	222
Clinical Indications	223
Conclusion	238
Suggested Readings	238
11. The Collection Facility	241
<i>Zbigniew M. Szczepiorkowski, MD, PhD, FCAP, FRSM; Thomas Zachary Thompson, MD, CABP; and Jeffrey L. Winters, MD</i>	
Regulatory Requirements and Voluntary Standards	242
Facility Design	244
Product, Supply, and Personnel Flow	247
Training and Competency of Personnel	248
Communication	248
Environmental Conditions	250
Storage	251
Cleaning, Sanitation, and Maintenance	252
Safety	253
Conclusions	254
Suggested Readings	254

12. The Processing Facility	255
<i>Thomas Zachary Thompson, MD, CABP, and Zbigniew M. Szczepiorkowski, MD, PhD, FCAP, FRSM</i>	
Two Major Product Classes	256
Facility Design	258
Product, Supply, and Personnel Flow	261
Communication	261
Environmental Conditions	262
Storage	262
Liquid Nitrogen	263
Cleaning, Sanitation, and Maintenance	263
Biosafety Cabinets	268
Conclusion	270
Suggested Readings	271
13. Cellular Therapy Quality Management	273
<i>Brian C. Jones, SBB(ASCP), CABP(H); Jeffrey L. Winters, MD; and Zbigniew M. Szczepiorkowski, MD, PhD, FCAP, FRSM</i>	
Regulatory Background	274
Cell Therapy Accreditations	276
Major Aspects of Quality Management	277
Suggested Readings	284
14. Regulations and Standards for Apheresis Centers	287
<i>Beth Kuker and Petr Machalik</i>	
US Federal and State Regulation	288
European Union Regulation	291
Industry Standards	293
Conclusion	297
Suggested Readings	297
15. Labeling of Cellular Therapy Products	299
<i>Zbigniew M. Szczepiorkowski, MD, PhD, FCAP, FRMS</i>	
Regulatory Requirements	300
ICCBBA Documents	302
Key Elements of ISBT 128	302
ISBT 128 Implementation and Maintenance	311
ICCBBA	313
Conclusions	314
Suggested Readings	314
Index	317